Method for solubilizing carboxylic acid-containing compound in hydrocarbon solvent

Information

  • Patent Grant
  • 9051417
  • Patent Number
    9,051,417
  • Date Filed
    Saturday, March 16, 2013
    11 years ago
  • Date Issued
    Tuesday, June 9, 2015
    9 years ago
Abstract
A method for increasing the solubility of a hydrocarbon compound comprising an aliphatic or arene moiety substituted with at least one acyl halide and at least one carboxylic acid functional group within a hydrocarbon solvent, wherein the method includes the step of preparing a solution comprising: at least 80 v/v % of the hydrocarbon solvent, the hydrocarbon compound, and a tri-hydrocarbyl phosphate compound, wherein the concentration of the hydrocarbon compound is greater than its solubility limit within the solvent but less than its solubility limit in the solution and the hydrocarbon.
Description
FIELD OF THE INVENTION

The present invention is directed toward methods for increasing the solubility of carboxylic acid-containing compounds within a variety of hydrocarbon solvents.


BACKGROUND

Compounds including carboxylic acid functional groups generally have poor solubility in hydrocarbon solvents. For example, hydrocarbon compounds including an aliphatic or arene moiety substituted with at least one acyl halide and at least one carboxylic acid functional group generally have solubilities below 0.02 weight percent in paraffinic solvents. Techniques for increasing the solubility of such compounds are desired. The resulting solutions would be useful in a variety of applications including the preparation of polyamides.


BRIEF SUMMARY OF THE INVENTION

The present invention includes a method for increasing the solubility of a hydrocarbon compound comprising an aliphatic or arene moiety substituted with at least one acyl halide and at least one carboxylic acid functional group within a hydrocarbon solvent, wherein the method comprises the step of preparing a solution comprising:


i) at least 80 v/v % of the hydrocarbon solvent,


ii) the hydrocarbon compound, and


iii) a tri-hydrocarbyl phosphate compound represented by:




embedded image


wherein R1, R2 and R3 are independently selected from hydrogen and hydrocarbyl groups comprising from 1 to 10 carbon atoms, with the proviso that no more than one of R1, R2 and R3 are hydrogen;


wherein the concentration of the hydrocarbon compound is greater than its solubility limit within the solvent but less than its solubility limit in the solution.







DETAILED DESCRIPTION OF THE INVENTION

The hydrocarbon compounds of the present invention include an aliphatic or arene moiety including at least one (and preferably only one) carboxylic acid functional group and at least one acyl halide functional group and are hereinafter referred to as “carboxylic acid-containing compound,” “hydrocarbon compound” or simply “compound.” In a preferred set of embodiments, the compound has a molecular weight less than 700, 600, 500, 400 or 300 Daltons. In another set of embodiments, the compound comprises equal to or less than 30, 20, 15 or 12 carbon atoms, and preferably includes more than 3 carbon atoms. In yet another set of embodiments, the compound comprises from 4 to 12 carbon atoms. Non-limiting examples of compounds based upon aliphatic moieties include: 4-chloro-4-oxobutanoic acid, 5-chloro-5-oxopentanoic acid, 6-chloro-6-oxohexanoic acid, 7-chloro-7-oxoheptanoic acid, 8-chloro-8-oxooctanoic acid, 9-chloro-9-oxononanoic acid, 10-chloro-10-oxodecanoic acid, 11-chloro-11-oxoundecanoic acid, 12-chloro-12-oxododecanoic acid; 3-(chlorocarbonyl)cyclobutanecarboxylic acid, 3-(chlorocarbonyl)cyclopentane carboxylic acid, 2,4-bis(chlorocarbonyl)cyclopentanecarboxylic acid, 3,5-bis(chlorocarbonyl) cyclohexanecarboxylic acid and 4-(chlorocarbonyl)cyclohexanecarboxylic acid. Non-limiting examples of compounds based upon arene moieties include: 4-(chlorocarbonyl) benzoic acid, 3,5-bis(chlorocarbonyl)benzoic acid, 7-(chlorocarbonyl)-2-naphthoic acid and 5,7-bis(chlorocarbonyl)-2-naphthoic acid. Additional examples of applicable compounds include branched analogs of the preceding compounds along with analogs including additional acyl halide functional groups or carboxylic acid functional groups.


The selection of hydrocarbon solvent is not particularly limited and combinations of multiple solvents may be used. The solvent is preferably a liquid at 20° C. (101 kPa). The solvent preferably has a water solubility of less than 800 ppm (and more preferably less than 500, 400, 300, or 200, or in some embodiments, less than 150 ppm). As used herein, the term “water solubility” refers to the concentration of water that is soluble in a chosen hydrocarbon solvent measured at 20° C. (101 kPa) as measured by ASTM D4928-11. Non-limiting examples of applicable hydrocarbon solvents include: paraffins (e.g. hexane, cyclohexane, heptane, octane, dodecane), isoparaffins (e.g. ISOPAR™ L), aromatics (e.g. benzene, 1,3,5-trimethylbenzene, toluene) and halogenated hydrocarbons (e.g. FREON™ series, chlorobenzene, di- and trichlorobenzene).


Tri-hydrocarbyl phosphate compounds applicable in the present invention include those represented by Formula (I):




embedded image


wherein “P” is phosphorous, “O” is oxygen and R1, R2 and R3 are independently selected from hydrogen and hydrocarbyl groups comprising from 1 to 10 carbon atoms, with the proviso that no more than one of R1, R2 and R3 are hydrogen. R1, R2 and R3 are preferably independently selected from aliphatic and arene groups. Applicable aliphatic groups include both branched an unbranched species, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, 2-pentyl, 3-pentyl, cyclopentyl, hexyl, 2-ethylhexyl, cyclohexyl, etc.; however, alkyl groups having from 3 to 10 carbon atoms are preferred. Applicable arene groups include phenyl and napthyl groups. Specific examples tri-hydrocarbyl phosphate compounds include: tripropyl phosphate, tributyl phosphate, tripentyl phosphate, trihexyl phosphate, triphenyl phosphate, propyl biphenyl phosphate, dibutyl phenyl phosphate, butyl diethyl phosphate, dibutyl hydrogen phosphate, butyl heptyl hydrogen phosphate and butyl heptyl hexyl phosphate.


The solution may further include additional constituents including a polyfunctional acyl halide compound including an aliphatic or arene moiety substituted with a plurality of acyl halide functional groups. Non-limiting examples include: C4 through C12 alkanes (e.g. succinyl, glutaroyl, adipoyl, heptanedioyl, octanedioyl, nonanedioyl, decanedioyl, undecanedioyl and dodecanedioyl di and tri chloride), cycloalkanes (e.g. cyclopropane tri carboxylic acid chloride, cyclobutane tetra carboxylic acid chloride, cyclopentane tri carboxylic acid chloride, cyclopentane tetra carboxylic acid chloride, cyclohexane tri carboxylic acid chloride, tetrahydrofuran tetra carboxylic acid chloride, cyclopentane dicarboxylic acid chloride, cyclobutane dicarboxylic acid chloride, cyclohexane di carboxylic acid chloride, tetrahydrofuran dicarboxylic acid chloride, cyclohexane dichloride, cyclohexane-1,3,5-tricarbonyl trichloride, and decahydronaphthalene-2,6-dicarbonyl dichloride. Non-limiting examples of reactants based upon arene moieties include: terephthaloyl dichloride, isophthalic acid chloride, benzene-1,3,5-tricarbonyl trichloride and naphthalene-2,6-dicarbonyl dichloride. Additional examples of reactants include branched analogs of the preceding compounds along analogs including additional acyl halide functional groups.


The aforementioned constituents are combined to form a solution comprising at least 80 v/v % hydrocarbon solvent, and in some embodiments at least 90 v/v %, 92 v/v % or 95 v/v % hydrocarbon solvent. In one set of embodiments, the hydrocarbon compound is provided a concentration of at least 0.01 wt %, 0.02 wt %, 0.03 wt %, 0.04 wt %, 0.05 wt %, 0.06 wt % or 0.1 wt %. In another set of embodiments, the solution comprises from 0.01 to 5 wt %, 0.02 to 2 wt %, 0.04 to 2 wt % or 0.05 to 2 wt % of the hydrocarbon compound. In yet another set of embodiments, the solutions comprises from 0.01 to 10 wt % of the tri-hydrocarbyl phosphate compound. The aforementioned constituents may be combined and mixed within a reaction vessel at room temperature.


In many embodiments, the hydrocarbon compound has a solubility limit of less than 1 wt. % in the hydrocarbon solvent, and in some embodiments less than 0.1 wt. %, 0.05 wt %, 0.02 wt % and still others less than even 0.01 wt %. While not wishing to be bound by theory, it is believed that the subject class of tri-hydrocarbyl phosphates increases the solubility of the subject hydrocarbon compounds within the hydrocarbon solvent (e.g. increase of at least 10%). Hydrocarbon-based solutions including relatively higher concentrations of the subject hydrocarbon compounds are useful in a variety of applications including coating operations to prepare polyamides.


Many embodiments of the invention have been described and in some instances certain embodiments, selections, ranges, constituents, or other features have been characterized as being “preferred.” Characterizations of “preferred” features should in no way be interpreted as deeming such features as being required, essential or critical to the invention. For purposes of this description, the terms “acyl halide” and “acid halide” have the same meaning. While much of the description has focused upon acyl chlorides, non-chloride halides are also included. The term “solubility limit” refers to the point at which no additional amount of a constituent, (e.g. water, reaction product, hydrocarbon reactant) is miscible or dissolvable with the hydrocarbon solvent or solution, as measured at 20° C. and 101 kPa. Unless otherwise stated, all solubility related parameters are determined at 20° C. and 101 kPa.


EXAMPLES

Preparation of mono-hydrolyzed polyfunctional acid chlorides:


High purity mono-hydrolyzed polyfunctional acid chlorides can be obtained via a variety of routes, including for example, preparing a starter solution by combining a polyfunctional acid chloride (many of which are commercially available including for example, trimesoyl chloride (TMC) and isophthaloyl chloride (IPC)), trialkylphosphate (e.g. tributylphosphate (TBP) and triethylphosphate, (TEP)), and trace levels of water in 100 mL of non-polar solvent in quantities described as separate entries in the table below. The starter solution is allowed to stir for 14-20 hours after which time an additional 1 g of the polyfunctional acid chloride and 0.0076 mL of water is added. The solution is allowed to stir for 1-2 hours and an additional 0.0076 mL of water is added. This is repeated until a total of 4 additions of 0.0076 mL of water are added to the starter solution. During the reaction, the mono-hydrolyzed polyfunctionalized acid chloride product precipitates out of the solution. The white precipitate can be collected using filter paper and washed repeatedly with fresh solvent yielding high purity mono-hydrolyzed polyfunctional acid chloride.















TABLE 1








Acid




Product












Example
Chloride
Additive

Water
Selectivity














No.
type
wt %
type
wt %
Solvent
(ppm)
(%)

















1-1
TMC
1.2
TBP
0.56
Isopar L
100
99


1-2
IPC
1.0
TBP
0.48
Isopar L
20
100


1-3
TMC
2.0
TEP
0.65
Isopar L
20
100


1-4
TMC
3.9
TEHP
1.30
Isopar L
20
94.8


1-5
TMC
2.0
TBP
0.65
90/10 Isopar
20
100







L/toluene











Solubility measurement of acid chlorides containing one carboxylic acid moiety in hydrocarbon solvents with and without solubility enhancing additives:


Saturated solutions of sample acid chlorides containing carboxylic acid moieties were prepared in hydrocarbon solvents with and without the presence of trialkylphosphate additives by adding more sample than will dissolve in the solvent and decanting the saturated solvent from the undissolved precipitate. The saturated solutions were evaluated by proton NMR. Deuterated Isopar L is not commercially available, thus all spectra were acquired in the unlocked condition using regular Isopar L. Because of the very high proton concentration in running a non-deuterated solvent, 60° pulse and minimum receiver gain were used to avoid receiver overflow. A relaxation delay of 8 seconds was used for complete signal recovery between scans. The spectral width was set to 20 ppm and the center of the spectrum was set to 5 ppm. Depending on the concentrations of the species of interest, 64-256 scans were used for signal averaging.


An example of the spectra analysis and calculations used to determine the solubility is provide below for an Isopar solution of mono-hydrolyzed trimesoyl chloride (mhTMC) with and without TBP. The area of the Isopar L peaks between 0.75 and 2.0 ppm were measure and divided by 26 (which represents the average H's present in Isopar L, assuming a molecular formula of C12H26) and multiplied by 170.33, the formula weight of C12H26. The peak area of the aromatic acid chlorides containing carboxylates are between 8.9-9.2 ppm and are well resolved from the Isopar solvent. The integration of one of the assigned peaks (for example, the triplet of mono-hydrolyzed TMC at 9.0 ppm represents a single proton) was used to determine the relative weight of the sample in the Isopar L solvent. The integration is divided by the number of protons it represents and multiplied by the formula weight of the compound it represents (for example, the triplet of mono-hydrolyzed TMC at 9.0 ppm would be divided by 1 and multiplied by 247.03 g/mol). The wt % of mono-hydrolyzed TMC in the saturated solution is determined by dividing the value obtained for mono-hydrolyzed TMC by the value obtained for Isopar L.


In the presence of tributylphosphate (TBP), the Isopar L value must be corrected since a few protons of TBP cannot be resolved from the Isopar L peaks. This is done by integrating the —OCH2-protons of TBP which are well resolved at ˜4.05 ppm, dividing this value by 6 (for 6 protons). This area value is then multiplied by 21 (represents the three —CH2CH2CH3 that are unresolved from the Isopar L peak) and subtracted from the peak area of Isopar L.












TABLE 2








Solubility


Example No.
Carboxylic acid
Solvent
(wt %)


















2-1
mhTMC
Isopar L
0.02


2-2
mhTMC
Isopar L + 1 wt % TEP
0.2


2-3
mhTMC
Isopar L + 1 wt % TEHP
0.11


2-4
mhTMC
80/20 Isopar L/Toluene +
0.29




0.25 wt % TBP


2-5
mhTMC
80/20 Isopar L/Toluene
0.05


2-5
mhIPC
Isopar L
<0.02


2-6
mhIPC
Isopar L + 0.47 wt % TBP
0.29








Claims
  • 1. A method for increasing the solubility of a hydrocarbon compound comprising an aliphatic or arene moiety substituted with at least one acyl halide and at least one carboxylic acid functional group within a hydrocarbon solvent, wherein the method comprises the step of preparing a solution comprising: i) at least 80 v/v % of the hydrocarbon solvent,ii) the hydrocarbon compound, andiii) a tri-hydrocarbyl phosphate compound represented by:
  • 2. The method of claim 1 wherein the hydrocarbon compound and tri-hydrocarbyl phosphate compound are provided in a molar ratio of from 1:1000 to 2:1.
  • 3. The method of claim 1 wherein the molar ratio of the hydrocarbon compound and tri-hydrocarbyl phosphate compound is from 1:100 to 1:1.
  • 4. The method of claim 1 wherein the solution comprises at least 0.02 weight percent of the hydrocarbon compound.
  • 5. The method of claim 1 wherein the solution comprises at least 0.05 weight percent of the hydrocarbon compound.
  • 6. The method of claim 1 wherein the hydrocarbon compound comprises equal to or less than 30 carbon atoms.
  • 7. The method of claim 1 wherein the hydrocarbon compound comprises from 4 to 12 carbon atoms.
  • 8. The method of claim 1 wherein the hydrocarbon compound comprises a single carboxylic acid functional group.
  • 9. The method of claim 1 wherein the hydrocarbon solvent has a water solubility of less than 150 ppm.
  • 10. The method of claim 1 wherein R1, R2 and R3 are independently selected from: aliphatic and arene groups.
  • 11. The method of claim 1 wherein the solution further comprises a polyfunctional acyl halide compound comprising no carboxylic acid functional groups.
US Referenced Citations (84)
Number Name Date Kind
3304310 Istvan Hari et al. Feb 1967 A
3686116 Andre Rio Aug 1972 A
3878109 Ikeda et al. Apr 1975 A
4259183 Cadotte Mar 1981 A
4265745 Kawaguchi et al. May 1981 A
4277344 Cadotte Jul 1981 A
4529646 Sundet Jul 1985 A
4606943 Rak et al. Aug 1986 A
4626468 Sundet Dec 1986 A
4643829 Sundet Feb 1987 A
4719062 Sundet Jan 1988 A
4758343 Sasaki et al. Jul 1988 A
4761234 Uemura et al. Aug 1988 A
4783346 Sundet Nov 1988 A
4812270 Cadotte et al. Mar 1989 A
4830885 Tran et al. May 1989 A
4888116 Cadotte et al. Dec 1989 A
4948507 Tomaschke Aug 1990 A
4950404 Chau Aug 1990 A
4960517 Cadotte Oct 1990 A
5015380 Sundet May 1991 A
5015382 Sundet May 1991 A
5019264 Arthur May 1991 A
5051178 Uemura et al. Sep 1991 A
5160619 Yamaguchi et al. Nov 1992 A
5246587 Tomaschke Sep 1993 A
5254261 Tomaschke et al. Oct 1993 A
5290452 Schucker Mar 1994 A
5336409 Hachisuka et al. Aug 1994 A
5510527 Hachisuka et al. Apr 1996 A
5576057 Hirose et al. Nov 1996 A
5582725 McCray et al. Dec 1996 A
5593588 Kim et al. Jan 1997 A
5614099 Hirose et al. Mar 1997 A
5616249 Hodgdon Apr 1997 A
5693227 Costa Dec 1997 A
5733602 Hirose et al. Mar 1998 A
5736371 Samain et al. Apr 1998 A
5744039 Itoh et al. Apr 1998 A
5783079 Kumano et al. Jul 1998 A
5843351 Hirose et al. Dec 1998 A
5876602 Jons et al. Mar 1999 A
5989426 Hirose et al. Nov 1999 A
6024873 Hirose et al. Feb 2000 A
6086764 Linder et al. Jul 2000 A
6162358 Li et al. Dec 2000 A
6280853 Mickols Aug 2001 B1
6337018 Mickols Jan 2002 B1
6406626 Murakami et al. Jun 2002 B1
6464873 Tomaschke Oct 2002 B1
6521130 Kono et al. Feb 2003 B1
6562266 Mickols May 2003 B2
6723241 Mickols Apr 2004 B2
6723422 Hirose et al. Apr 2004 B1
6878278 Mickols Apr 2005 B2
7279097 Tomioka et al. Oct 2007 B2
7806275 Murphy et al. Oct 2010 B2
7815987 Mickols et al. Oct 2010 B2
7882963 Mickols et al. Feb 2011 B2
7905361 Niu et al. Mar 2011 B2
7918349 Mickols et al. Apr 2011 B2
8147735 Buschmann Apr 2012 B2
8177978 Kurth et al. May 2012 B2
20080185332 Niu et al. Aug 2008 A1
20090071903 Nakatsuji et al. Mar 2009 A1
20090107922 Zhang et al. Apr 2009 A1
20090220690 Niu et al. Sep 2009 A1
20090272692 Kurth et al. Nov 2009 A1
20100062156 Kurth et al. Mar 2010 A1
20110005997 Kurth et al. Jan 2011 A1
20110049055 Wang et al. Mar 2011 A1
20110220569 Mickols et al. Sep 2011 A1
20120248027 Sasaki et al. Oct 2012 A1
20120261332 Takagi et al. Oct 2012 A1
20120261344 Kurth et al. Oct 2012 A1
20120305473 Ogawa et al. Dec 2012 A1
20130089727 Nilsen et al. Apr 2013 A1
20130126419 Ogawa et al. May 2013 A1
20130256215 Nakatsuji et al. Oct 2013 A1
20140199483 Roy et al. Jul 2014 A1
20140206900 Qiu et al. Jul 2014 A1
20140264161 Roy et al. Sep 2014 A1
20140264162 Qiu et al. Sep 2014 A1
20140272134 Roy et al. Sep 2014 A1
Foreign Referenced Citations (27)
Number Date Country
1035338 Jul 1997 CN
102219673 Oct 2011 CN
2530562 Jan 1977 DE
0302149 Feb 1989 EP
53146275 Dec 1978 JP
2009129354 Oct 2009 WO
2010042250 Apr 2010 WO
2010120326 Oct 2010 WO
2010120327 Oct 2010 WO
2011105278 Sep 2011 WO
2012020680 Feb 2012 WO
2012090862 Jul 2012 WO
2012102942 Aug 2012 WO
2012102943 Aug 2012 WO
2012102944 Aug 2012 WO
2013032586 Mar 2013 WO
2013048762 Apr 2013 WO
2013048763 Apr 2013 WO
2013048764 Apr 2013 WO
2013048765 Apr 2013 WO
2013103666 Jul 2013 WO
2014014662 Jan 2014 WO
2014014663 Jan 2014 WO
2014014664 Jan 2014 WO
2014014666 Jan 2014 WO
2014014668 Jan 2014 WO
2014014669 Jan 2014 WO
Non-Patent Literature Citations (5)
Entry
Marvel, et al., Journal of Organic Chemistry, vol. 18, No. 12, (1953) 1664-1669.
Dow Global Technologies LLC, PCT/US13/020072, filed Jan. 3, 2013.
Li et al, Polyamide thin fim composite membranes prepared from isomeric biphenyl tetrraacyl chloride and m-phenylenediamine, Journal of Membrane Science 315, (2008) 20-27.
U.S. Appl. No. 61/818,934, filed May 3, 2014, Composite Polyamide Membrane Derived From an Aliphatic Acyclic Tertiary Amine Compound, Paul Mou et al.
International Application PCT/US2014/010123, filed Jan. 3, 2014, Composite Polyamide Membrane Made Using Substituted Benzamide Monomer, Abhishek L. Roy, et al.
Related Publications (1)
Number Date Country
20140264162 A1 Sep 2014 US